Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis

BMJ Open

Volumn 3, Issue 4, 2013, Pages

  DiSantostefano, Rachael L ^a   Li, Hao ^a   Rubin, David B ^a   Stempel, David A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; SALMETEROL XINAFOATE;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLUSTER ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; SMOKING; TREATMENT RESPONSE;

EID: 84877784528     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-001838     Document Type: Article

References (49)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2011. http://www.goldcopd.org/ (accessed 1 Jun 2012).
2. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-8.
3. Spencer S, Calverley PM, Burge PS, et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004;23:698-702. (Pubitemid 38618138)
4. Jones PW, Tabberer M, Chen WH. Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT™) scores. BMC Pulm Med 2011;11:42.
5. Agusti AG. COPD, a multicomponent disease: implications for management. Respir Med 2005;99:670-82. (Pubitemid 40631293)
6. Agusti A, Calverley P, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11:122.
7. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010;182:598 -604.
8. Hurst JR, Vestbo J, Anzueto A. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New Engl J Med 2010;363:1128-38.
9. Cho MH, Washko GR, Hoffmann TJ, et al. Cluster analysis in severe emphysema subjects using phenotype and genotype data: an exploratory investigation. Respir Res 2010;11:30.
10. Roy K, Smith J, Kolsum U, et al. COPD phenotype description using principal components analysis. Respir Res 2009;10:41.
11. Garcia-Aymerich J, Gomez F, Benet M, et al . Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD subtypes). Thorax 2011;66:430-7.
12. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:728-35.
13. Su X, Tsai C-L, Wang H, et al. Tree-based subgroup analysis via recursive partitioning. J Mach Learn Res 2009;10:141-58.
14. Anzueto A, Feldman G, Chinsky K, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. J COPD 2009;6:320-9.
15. Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 mcg) or salmeterol (50 mcg) on COPD exacerbations. Respir Med 2008;102:1099-108.
16. American Thoracic Society Standards for diagnosis and care of patients with chronic obstructive pulmonary disease and asthma. Am Rev Respir Dis 1987;136:225-44.
17. WHO Collaborating Centre for Drug Statistics Methodology. Structure and principles of the Anatomical Therapeutic Chemical (ATC) classification system. http://www.whocc.no/atc/structure-and-principles/ (accessed 20 Feb 2013).
18. Everitt B. An R and S-PLUS companion to multivariate analysis. London: Springer-Verlag, 2005.
19. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26:948-68. (Pubitemid 41632054)
20. Poulain M, Doucet M, Drapeau V, et al. Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary disease. Chron Respir Dis 2008;5:35-41. (Pubitemid 351903614)
21. Man SF, Leipsic JA, Man JP, et al. Is atherosclerotic heart disease in COPD a distinct phenotype? Chest 2011;140:569-71.
22. Niewoehner DE, Lokhnygina Y, Rice K, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007;131:20-8. (Pubitemid 46122970)
23. Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011;66:764-8.
24. Groenewegen KH, Postma DS, Hop WC, et al. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008;133:350-7. (Pubitemid 351272391)
25. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:155-61.
26. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89. (Pubitemid 46294610)
27. TORCH CV, Calverley PM, Anderson JA, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010;65:719-25.
28. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:1259-65. (Pubitemid 46905751)
29. Dransfield MT, Cockcroft JR, Townsend RR, et al. Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD. Respir Med 2011;105:1322-30.
30. Yuengsrigul A, Chin TW, Nussbaum E. Immunosuppressive and cytotoxic effects of furosemide on human peripheral blood mononuclear cells. Ann Allergy Asthma Immunol 1999;83:559-66. (Pubitemid 30013516)
31. Prandota J. Furosemide: progress in understanding its diuretic, anti-inflammatory, and bronchodilating mechanism of action, and use in the treatment of respiratory tract diseases. Am J Ther 2002;9:317-28.
32. Jensen D, Amjadi K, Harris-McAllister V, et al. Mechanism of dyspnoea relief and improved exercise after furosemide inhalation in COPD. Thorax 2008;63:606-13. (Pubitemid 351969253)
33. Roger A, Botey J, Esevrri JL, et al. Prevention of exercise-induced asthma in children using low doses of inhaled furosemide. J Invest Allergol Clin Immunol 1993;3:300-3. (Pubitemid 24051380)
34. Novembre E, Frongia G, Lombardi E, et al. The preventative effect and duration of action of two doses of inhaled furosemide on exercise-induced asthma in children. J Allergy Clin Immunol 1995;96:906-9.
35. Melo RE, Sole D, Naspitz CK. Comparative efficacy of inhaled furosemide and disodium cromoglycate in the treatment of exercise-induced asthma in children. J Allergy Clin Immunol 1997;99:204-9. (Pubitemid 27091569)
36. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33:1165-85.
37. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012;380:37-43.
38. Guthrie B, Payne K, Alderson P, et al. Adapting clinical guidelines to take account of multimorbidity. BMJ 2012;345:e6341.
39. Hanania N, Celli BR, Donohue JF, et al. Bronchodilator reversibility in COPD. Chest 2011;140:1055-63.
40. Jones PW, Donohue JF, Nedelman J, et al. Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res 2011;12:161.
41. Bleecker ER, Emmett A, Crater G, et al. Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility. Pulm Pharmacol Ther 2008;21:682-8.
42. Albert P, Agusti A, Edwards L, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax 2012;68:701-8.
43. Soriano JB, Sin DD, Zhang X, et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 2007;131:682-9. (Pubitemid 46446857)
44. Postma DS, Boezen HM. Rationale for the Dutch hypothesis. Allergy and airway hyperresponsiveness as genetic factors and their interaction with environment in the development of asthma and COPD. Chest 2004;126(Suppl 2):96S-104S. (Pubitemid 39093398)
45. de Oca MM, Halbert RJ, Lopez MV, et al. The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. Eur Respir J 2012;40:28-36.
46. Soler-Cataluña JJ, Cosío B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol 2012;48:331-7.
47. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;184:662-71.
48. Burgel P-R, Paillasseur J-L, Caillaud D, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010;36:531-9.
49. Weatherall M, Travers J, Shirtcliffe PM, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Repir J 2009;34:812-18.